Federico Pérez Manghi

Author

Also Known As

Cecilia Luquez, F Manghi, F. Perez Manghi, Federico C Pérez Manghi, Federico P. Manghi, Federico Perez Manghi, Federico Pérez Manghi, García-Hernández, Pedro, Laura Maffei, Pardeep Jhund Singh

Publications

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Centro de Investigaciones Cardiovasculares The University of Texas Southwestern Medical Center

About

Federico Pérez Manghi is an author at Eli Lilly (United States) specializing in medicine, diabetes, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	1.8K
2	Diabetes	2	2	1.7K
3	Hepatology	1	1	66
4	Pharmacology	1	1	66
5	Clinical Trials	1	1	1.7K

Federico Pérez Manghi

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, The Lancet Diabetes ManagementCardiovascular DiseaseDiabetesClinical TrialsType 2	2018	1.7K
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3) Guillermo E. Umpierrez, Santiago Tofé, Federico Pérez Manghi, Diabetes Care	2014	323
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes Ildiko Lingvay, Federico Pérez Manghi, Pedro Alberto García-Hernández, JAMA	2016	208
A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes ( <scp>AWARD</scp> ‐8) Kathleen Dungan, Raimund Weitgasser, Federico Pérez Manghi, Diabetes Obesity and Metabolism	2016	95
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study Stephen A. Harrison, Federico Pérez Manghi, William B. Smith, Nature Medicine HepatologyMedicineNonalcoholic SteatohepatitisLiver DiseaseFatty Liver Disease	2022	66
Efficacy and Safety of Dulaglutide in Hispanic/Latino Patients with Type 2 Diabetes in the Award Clinical Program Jaime A. Davidson, Federico Pérez Manghi, Maria Yu, Endocrine Practice Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseAward Clinical ProgramDiabetes	2016	14
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial Thomas Blevins, Dominik Dahl, Federico Pérez Manghi, The Lancet	2025	13

Page 1